Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Afatinib is a promising irreversible EGFR/HER2/HER4 inhibitor for head and neck squamous cell carcinoma (HNSCC).
• The precise molecular mechanisms driving afatinib-induced apoptosis in HNSCC remain unclear.
• Understanding these mechanisms is crucial for optimizing afatinib's clinical efficacy.

Purpose of the Study:

• To elucidate the molecular pathways mediating afatinib-induced apoptosis in HNSCC.
• To identify key proteins and signaling cascades involved in afatinib's anti-cancer effects.
• To provide a mechanistic basis for the clinical application of afatinib in HNSCC.

Main Methods:

• Investigated the role of MCL-1 (an anti-apoptotic BCL-2 family member) in afatinib-treated HNSCC cells.
• Analyzed the impact of afatinib on AKT-mTOR signaling pathways.
• Examined the involvement of the endoplasmic reticulum (ER) stress PERK-eIF2α-ATF4 axis.
• Utilized siRNA to silence eIF2α or ATF4 and assessed effects on signaling and apoptosis.

Main Results:

• Afatinib induces apoptosis in HNSCC cells through the down-regulation of MCL-1.
• Afatinib inactivates AKT-mTOR signaling, leading to translational inhibition of MCL-1.
• Afatinib stimulates the PERK-eIF2α-ATF4 ER stress pathway.
• Silencing eIF2α or ATF4 restores AKT-mTOR activity and MCL-1 levels, reducing apoptosis.

Conclusions:

• Afatinib induces apoptosis in HNSCC by activating the PERK-eIF2α-ATF4 pathway, which suppresses AKT-mTOR signaling and subsequently down-regulates MCL-1.
• This study reveals a complex molecular network underlying afatinib's action in HNSCC.
• Findings support afatinib's therapeutic potential and provide targets for enhancing its efficacy in HNSCC treatment.